Patent application number | Description | Published |
20090131399 | Imidazopyridine Derivatives Useful as iNOS Inhibitors - The compounds of formula (I) | 05-21-2009 |
20100317650 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS - The compounds of formula (I) | 12-16-2010 |
20110060050 | SGK1 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF VIRAL DISEASES AND/OR CARCINOMAS - The present invention relates to a compound of the formula I, Ia and Ib, and its pharmaceutically usable tautomers, salts, stereoisomers and the enantiomers, including mixtures thereof in all ratios. The present invention furthermore also relates to compounds of the formula II for the prophylaxis and/or treatment of viral diseases and/or carcinomas, in which R | 03-10-2011 |
20110224302 | DIFLUOROPHENYLDIACYLHYDRAZIDE DERIVATIVES - Novel difluorophenyldiacylhydrazide derivatives of the formula I, in which R | 09-15-2011 |
20130012489 | Morpholinylquinazolines - The invention relates to compounds of the formulae (I), (II) and (III) | 01-10-2013 |
20130150359 | PYRAZOLOQUINOLINES - The invention relates to compounds of the formulae (I), (II) and (III), and/or physiologically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. The compounds of the formula (I) can be used for the inhibition of serine/threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of cancer, tumours, metastases or angiogenesis disorders, in combination with radiotherapy and/or an anticancer agent. The invention furthermore relates to a process for the preparation of the compounds of the formula (I) by reaction of compounds of the formula (II) or (III) and optionally conversion of a base or acid of the compounds of the formula (I) into one of its salts | 06-13-2013 |
20130172337 | Imidazo[4,5-c]quinolines as DNA-PK inhibitors - The invention relates to compounds of the formulae (I) and (II) in which R1, R2, R3, R4, R5, R8, X and m have the meaning indicated in the claims, and/or physiologically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. The compounds of the formula (I) can be used for the inhibition of serine/threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of cancer, tumours, metastases or angiogenesis disorders, in combination with radiotherapy and/or an anticancer agent. The invention furthermore relates to a process for the preparation of the compounds of the formula (I). | 07-04-2013 |
20140275072 | MORPHOLINYLBENZOTRIAZINES FOR USE IN CANCER THERAPY - The invention relates to compounds of the formula (I) in which R1, L and m have the meaning indicated in the claims, and/or physiologically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. | 09-18-2014 |